Shanghai Serum Bio-Technology's ROE and earnings retention a...

Shanghai Serum Bio-Technology's ROE and earnings retention are poor despite respectable earnings growth. High payout ratio and lower-than-average net income growth could risk the company's growth, especially in troubled times. The recent decision to pay dividends may be to impress shareholders.